文献速递产科母胎医学

妊娠期糖尿病与COVID-19:COVID-19相关产科与新生儿结局研究(CRONOS)结果

Gestational diabetes mellitus and COVID-19: results from the COVID-19-Related Obstetric and Neonatal Outcome Study (CRONOS).
PubMed 文献 · Am J Obstet Gynecol · 2022-05-14

CRONOS是一项德国及奥地利林茨的多中心前瞻性观察性登记研究,纳入1490例临床确诊COVID-19孕妇,其中140例(9.4%)合并妊娠期糖尿病。整体上妊娠期糖尿病与不良母体结局无关,但在超重或肥胖孕妇中独立关联不良母体结局及新生儿结局。

要点

  • 整体妊娠期糖尿病与不良母体结局无显著关联(OR 1.50,95%CI 0.88-2.57)。
  • 超重或肥胖合并妊娠期糖尿病者不良母体结局风险升高(aOR 2.69,95%CI 1.43-5.07)。
  • 妊娠期糖尿病需胰岛素治疗且超重或肥胖者重症COVID-19风险升高(aOR 3.05,95%CI 1.38-6.73)。

核心结论

  • 妊娠期糖尿病合并围受孕期超重或肥胖与COVID-19严重母体病程独立相关,尤其在需胰岛素治疗且COVID-19诊断于妊娠期糖尿病诊断同时或之后时。
  • 这些合并因素对新生儿结局呈中等程度影响。
  • 妊娠期糖尿病且体重指数≥25 kg/m2的孕妇在COVID-19情况下是特别脆弱的群体。

研究设计与样本

  • CRONOS为来自德国及奥地利林茨的登记型多中心前瞻性观察性研究。
  • 2020年4月3日至2021年8月24日期间纳入任何孕期的临床确诊COVID-19孕妇。
  • 115家医院的产科医生和新生儿科医生主动提供数据,通过基于云端的电子数据平台采集。
  • 纳入1490例COVID-19孕妇(平均年龄31.0±5.2岁;40.7%未产),其中140例(9.4%)诊断妊娠期糖尿病,42.9%接受胰岛素治疗。
  • 主要母体复合终点为入住重症监护室(含孕产妇死亡)、病毒性肺炎和/或补充氧气;主要胎儿及新生儿复合终点为≥24 0/7周妊娠的死产、分娩后≤7天新生儿死亡和/或转入新生儿重症监护室。

主要发现

  • 整体上妊娠期糖尿病与不良母体结局无关(OR 1.50,95%CI 0.88-2.57)。
  • 超重或肥胖女性中,妊娠期糖尿病与主要母体结局独立相关(aOR 2.69,95%CI 1.43-5.07)。
  • 超重或肥胖且妊娠期糖尿病需胰岛素治疗者重症COVID-19风险升高(aOR 3.05,95%CI 1.38-6.73)。
  • COVID-19诊断于妊娠期糖尿病诊断同时或之后者不良母体结局发生率19.6%,高于COVID-19诊断于妊娠期糖尿病诊断之前者的5.6%(P<.05)。
  • 母体妊娠期糖尿病和孕前体重指数≥25 kg/m2增加不良胎儿及新生儿结局风险(aOR 1.83,95%CI 1.05-3.18);与体重不足或正常体重相比,超重和肥胖(不论妊娠期糖尿病状态)是母体(aOR 1.87,95%CI 1.26-2.75)和新生儿(aOR 1.81,95%CI 1.32-2.48)主要终点的影晌因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational diabetes mellitus is one of the most frequent pregnancy complications with a global prevalence of 13.4% in 2021. Pregnant women with COVID-19 and gestational diabetes mellitus are 3.3 times more likely to be admitted to an intensive care unit than women without gestational diabetes mellitus. Data on the association of gestational diabetes mellitus with maternal and neonatal pregnancy outcomes in pregnant women with SARS-CoV-2 infection are lacking. OBJECTIVE: This study aimed to investigate whether gestational diabetes mellitus is an independent risk factor for adverse maternal and fetal and neonatal outcomes in pregnant women with COVID-19. STUDY DESIGN: The COVID-19-Related Obstetric and Neonatal Outcome Study is a registry-based multicentric prospective observational study from Germany and Linz, Austria. Pregnant women with clinically confirmed COVID-19 were enrolled between April 3, 2020, and August 24, 2021, at any stage of pregnancy. Obstetricians and neonatologists of 115 hospitals actively provided data to the COVID-19-Related Obstetric and Neonatal Outcome Study. For collecting data, a cloud-based electronic data platform was developed. Women and neonates were observed until hospital discharge. Information on demographic characteristics, comorbidities, medical history, COVID-19-associated symptoms and treatments, pregnancy, and birth outcomes were entered by the local sites. Information on the periconceptional body mass index was collected. A primary combined maternal endpoint was defined as (1) admission to an intensive care unit (including maternal mortality), (2) viral pneumonia, and/or (3) oxygen supplementation. A primary combined fetal and neonatal endpoint was defined as (1) stillbirth at ≥24 0/7 weeks of gestation, (2) neonatal death ≤7 days after delivery, and/or (3) transfer to a neonatal intensive care unit. Multivariable logistic regression analysis was performed to evaluate the modulating effect of gestational diabetes mellitus on the defined endpoints. RESULTS: Of the 1490 women with COVID-19 (mean age, 31.0±5.2 years; 40.7% nulliparous), 140 (9.4%) were diagnosed with gestational diabetes mellitus; of these, 42.9% were treated with insulin. Overall, gestational diabetes mellitus was not associated with an adverse maternal outcome (odds ratio, 1.50; 95% confidence interval, 0.88-2.57). However, in women who were overweight or obese, gestational diabetes mellitus was independently associated with the primary maternal outcome (adjusted odds ratio, 2.69; 95% confidence interval, 1.43-5.07). Women who were overweight or obese with gestational diabetes mellitus requiring insulin treatment were found to have an increased risk of a severe course of COVID-19 (adjusted odds ratio, 3.05; 95% confidence interval, 1.38-6.73). Adverse maternal outcomes were more common when COVID-19 was diagnosed with or shortly after gestational diabetes mellitus diagnosis than COVID-19 diagnosis before gestational diabetes mellitus diagnosis (19.6% vs 5.6%; P<.05). Maternal gestational diabetes mellitus and maternal preconception body mass index of ≥25 kg/m2 increased the risk of adverse fetal and neonatal outcomes (adjusted odds ratio, 1.83; 95% confidence interval, 1.05-3.18). Furthermore, overweight and obesity (irrespective of gestational diabetes mellitus status) were influential factors for the maternal (adjusted odds ratio, 1.87; 95% confidence interval, 1.26-2.75) and neonatal (adjusted odds ratio, 1.81; 95% confidence interval, 1.32-2.48) primary endpoints compared with underweight or normal weight. CONCLUSION: Gestational diabetes mellitus, combined with periconceptional overweight or obesity, was independently associated with a severe maternal course of COVID-19, especially when the mother required insulin and COVID-19 was diagnosed with or after gestational diabetes mellitus diagnosis. These combined factors exhibited a moderate effect on neonatal outcomes. Women with gestational diabetes mellitus and a body mass index of ≥25 kg/m2 were a particularly vulnerable group in the case of COVID-19.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kleinwechter HJ, Weber KS, Mingers N, et al. Gestational diabetes mellitus and COVID-19: results from the COVID-19-Related Obstetric and Neonatal Outcome Study (CRONOS). Am J Obstet Gynecol. 2022. PMID: 35580632. doi:10.1016/j.ajog.2022.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。